287 related articles for article (PubMed ID: 21963514)
1. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors.
Benedetti F; Amanzio M; Rosato R; Blanchard C
Nat Med; 2011 Oct; 17(10):1228-30. PubMed ID: 21963514
[TBL] [Abstract][Full Text] [Related]
2. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
[TBL] [Abstract][Full Text] [Related]
3. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
[TBL] [Abstract][Full Text] [Related]
4. Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor.
Shim JY; Welsh WJ; Cartier E; Edwards JL; Howlett AC
J Med Chem; 2002 Mar; 45(7):1447-59. PubMed ID: 11906286
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
6. Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles.
Dow RL; Hadcock JR; Scott DO; Schneider SR; Paight ES; Iredale PA; Carpino PA; Griffith DA; Hammond M; Dasilva-Jardine P
Bioorg Med Chem Lett; 2009 Sep; 19(18):5351-4. PubMed ID: 19683918
[TBL] [Abstract][Full Text] [Related]
7. Methoxy- and fluorine-substituted analogs of O-1302: synthesis and in vitro binding affinity for the CB1 cannabinoid receptor.
Tobiishi S; Sasada T; Nojiri Y; Yamamoto F; Mukai T; Ishiwata K; Maeda M
Chem Pharm Bull (Tokyo); 2007 Aug; 55(8):1213-7. PubMed ID: 17666847
[TBL] [Abstract][Full Text] [Related]
8. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies.
Le Foll B; Forget B; Aubin HJ; Goldberg SR
Addict Biol; 2008 Jun; 13(2):239-52. PubMed ID: 18482433
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse.
Fride E; Braun H; Matan H; Steinberg S; Reggio PH; Seltzman HH
Pediatr Res; 2007 Nov; 62(5):533-6. PubMed ID: 17805201
[TBL] [Abstract][Full Text] [Related]
10. Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling.
Shore DM; Baillie GL; Hurst DH; Navas F; Seltzman HH; Marcu JP; Abood ME; Ross RA; Reggio PH
J Biol Chem; 2014 Feb; 289(9):5828-45. PubMed ID: 24366865
[TBL] [Abstract][Full Text] [Related]
11. Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons.
Liu Q; Bhat M; Bowen WD; Cheng J
J Pharmacol Exp Ther; 2009 Dec; 331(3):1062-70. PubMed ID: 19752241
[TBL] [Abstract][Full Text] [Related]
12. Pyrazole antagonists of the CB1 receptor with reduced brain penetration.
Fulp A; Zhang Y; Bortoff K; Seltzman H; Snyder R; Wiethe R; Amato G; Maitra R
Bioorg Med Chem; 2016 Mar; 24(5):1063-70. PubMed ID: 26827137
[TBL] [Abstract][Full Text] [Related]
13. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
McCollum L; Howlett AC; Mukhopadhyay S
J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
[TBL] [Abstract][Full Text] [Related]
14. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA
J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies.
Ferrer B; Gorriti MA; Palomino A; Gornemann I; de Diego Y; Bermudez-Silva FJ; Bilbao A; Fernandez-Espejo E; Moratalla R; Navarro M; Rodríguez de Fonseca F
Eur J Pharmacol; 2007 Mar; 559(2-3):180-3. PubMed ID: 17291487
[TBL] [Abstract][Full Text] [Related]
16. Facile synthesis, ex-vivo and in vitro screening of 3-sulfonamide derivative of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide (SR141716) a potent CB1 receptor antagonist.
Kumar Srivastava B; Soni R; Patel JZ; Jha S; Shedage SA; Gandhi N; Sairam KV; Pawar V; Sadhwani N; Mitra P; Jain MR; Patel PR
Bioorg Med Chem Lett; 2008 Jul; 18(14):3882-6. PubMed ID: 18585913
[TBL] [Abstract][Full Text] [Related]
17. Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor.
Khajehali E; Malone DT; Glass M; Sexton PM; Christopoulos A; Leach K
Mol Pharmacol; 2015 Aug; 88(2):368-79. PubMed ID: 26044547
[TBL] [Abstract][Full Text] [Related]
18. Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?
Doggrell SA
Expert Opin Investig Drugs; 2005 Mar; 14(3):339-42. PubMed ID: 15833065
[No Abstract] [Full Text] [Related]
19. Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities.
Thomas BF; Francisco ME; Seltzman HH; Thomas JB; Fix SE; Schulz AK; Gilliam AF; Pertwee RG; Stevenson LA
Bioorg Med Chem; 2005 Sep; 13(18):5463-74. PubMed ID: 15994087
[TBL] [Abstract][Full Text] [Related]
20. Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation.
Makwana R; Molleman A; Parsons ME
Br J Pharmacol; 2010 Jun; 160(3):615-26. PubMed ID: 20590566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
